Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL

NCT02361346 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision following clinical hold

Conditions

Non-Hodgkin's B-cell Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell
Small Lymphocytic Leukemia
Diffuse Large B Cell Lymphoma
Blood Cancer
Hematological Malignancy

Interventions

DRUG: MT-3724 Phase 1
DRUG: MT-3724 Phase 2

Sponsor

Molecular Templates, Inc.